16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To clarify molecular alterations in serrated pathway of colorectal cancer (CRC), we performed epigenetic and genetic analyses in sessile serrated adenoma/polyps (SSA/P), traditional serrated adenomas (TSAs) and high‐methylation CRC. The methylation levels of six Group‐1 and 14 Group‐2 markers, established in our previous studies, were analyzed quantitatively using pyrosequencing. Subsequently, we performed targeted exon sequencing analyses of 126 candidate driver genes and examined molecular alterations that are associated with cancer development. SSA/P showed high methylation levels of both Group‐1 and Group‐2 markers, frequent BRAF mutation and occurrence in proximal colon, which were features of high‐methylation CRC. But TSA showed low‐methylation levels of Group‐1 markers, less frequent BRAF mutation and occurrence at distal colon. SSA/P, but not TSA, is thus considered to be precursor of high‐methylation CRC. High‐methylation CRC had even higher methylation levels of some genes, e.g., MLH1, than SSA/P, and significant frequency of somatic mutations in nonsynonymous mutations ( p < 0.0001) and insertion/deletions ( p = 0.002). MLH1‐methylated SSA/P showed lower methylation level of MLH1 compared with high‐methylation CRC, and rarely accompanied silencing of MLH1 expression. The mutation frequencies were not different between MLH1‐methylated and MLH1‐unmethylated SSA/P, suggesting that MLH1 methylation might be insufficient in SSA/P to acquire a hypermutation phenotype. Mutations of mismatch repair genes, e.g., MSH3 and MSH6, and genes in PI3K, WNT, TGF‐β and BMP signaling (but not in TP53 signaling) were significantly involved in high‐methylation CRC compared with adenoma, suggesting importance of abrogation of these genes in serrated pathway.

          Abstract

          What's new?

          The serrated pathway of colorectal cancer (CRC) development is characterized by the presence of saw‐toothed colonic crypts and by a high‐methylation epigenotype. Not all serrated lesions, however, give rise to CRC. Here, only sessile serrated adenoma/polyps, a potentially malignant serrated polyp subtype, were identified as precursors of high‐methylation CRC. Moreover, MLH1 expression, silencing of which previously was linked to microsatellite instability in CRC, was found to be preserved in most serrated adenoma/polyp samples. The findings suggest that the acquisition of a hypermutation phenotype in serrated CRC likely depends on extensive MLH1 methylation and mutation of additional mismatch repair genes.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Patterns of somatic mutation in human cancer genomes.

          Cancers arise owing to mutations in a subset of genes that confer growth advantage. The availability of the human genome sequence led us to propose that systematic resequencing of cancer genomes for mutations would lead to the discovery of many additional cancer genes. Here we report more than 1,000 somatic mutations found in 274 megabases (Mb) of DNA corresponding to the coding exons of 518 protein kinase genes in 210 diverse human cancers. There was substantial variation in the number and pattern of mutations in individual cancers reflecting different exposures, DNA repair defects and cellular origins. Most somatic mutations are likely to be 'passengers' that do not contribute to oncogenesis. However, there was evidence for 'driver' mutations contributing to the development of the cancers studied in approximately 120 genes. Systematic sequencing of cancer genomes therefore reveals the evolutionary diversity of cancers and implicates a larger repertoire of cancer genes than previously anticipated.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.

            Aberrant DNA methylation of CpG islands has been widely observed in human colorectal tumors and is associated with gene silencing when it occurs in promoter areas. A subset of colorectal tumors has an exceptionally high frequency of methylation of some CpG islands, leading to the suggestion of a distinct trait referred to as 'CpG island methylator phenotype', or 'CIMP'. However, the existence of CIMP has been challenged. To resolve this continuing controversy, we conducted a systematic, stepwise screen of 195 CpG island methylation markers using MethyLight technology, involving 295 primary human colorectal tumors and 16,785 separate quantitative analyses. We found that CIMP-positive (CIMP+) tumors convincingly represent a distinct subset, encompassing almost all cases of tumors with BRAF mutation (odds ratio = 203). Sporadic cases of mismatch repair deficiency occur almost exclusively as a consequence of CIMP-associated methylation of MLH1 . We propose a robust new marker panel to classify CIMP+ tumors.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              CpG island methylator phenotype in colorectal cancer.

              Aberrant methylation of promoter region CpG islands is associated with transcriptional inactivation of tumor-suppressor genes in neoplasia. To understand global patterns of CpG island methylation in colorectal cancer, we have used a recently developed technique called methylated CpG island amplification to examine 30 newly cloned differentially methylated DNA sequences. Of these 30 clones, 19 (63%) were progressively methylated in an age-dependent manner in normal colon, 7 (23%) were methylated in a cancer-specific manner, and 4 (13%) were methylated only in cell lines. Thus, a majority of CpG islands methylated in colon cancer are also methylated in a subset of normal colonic cells during the process of aging. In contrast, methylation of the cancer-specific clones was found exclusively in a subset of colorectal cancers, which appear to display a CpG island methylator phenotype (CIMP). CIMP+ tumors also have a high incidence of p16 and THBS1 methylation, and they include the majority of sporadic colorectal cancers with microsatellite instability related to hMLH1 methylation. We thus define a pathway in colorectal cancer that appears to be responsible for the majority of sporadic tumors with mismatch repair deficiency.
                Bookmark

                Author and article information

                Journal
                Int J Cancer
                Int. J. Cancer
                10.1002/(ISSN)1097-0215
                IJC
                International Journal of Cancer
                John Wiley and Sons Inc. (Hoboken )
                0020-7136
                1097-0215
                12 November 2015
                01 April 2016
                : 138
                : 7 ( doiID: 10.1002/ijc.v138.7 )
                : 1634-1644
                Affiliations
                [ 1 ] Department of GastroenterologyYokohama City University School of Medicine YokohamaJapan
                [ 2 ] Department of Molecular Oncology, Graduate School of MedicineChiba University ChibaJapan
                [ 3 ] Department of GastroenterologyKanto Medical Center, NTT East TokyoJapan
                [ 4 ] Department of Diagnostic PathologyKanto Medical Center, NTT East TokyoJapan
                [ 5 ] Department of Pathology, Graduate School of Medicine, Research Center for Advanced Science and Technology The University of Tokyo TokyoJapan
                [ 6 ] Division of Molecular Diagnosis and Cancer PreventionSaitama Cancer Center SaitamaJapan
                [ 7 ] Genome Science Division, Research Center for Advanced Science and TechnologyThe University of Tokyo TokyoJapan
                [ 8 ] CRESTJapan Agency for Medical Research and Development TokyoJapan
                Author notes
                [*] [* ] Correspondence to: Atsushi Kaneda, M.D., Ph.D., Department of Molecular Oncology, Graduate School of Medicine, Chiba University Inohana 1‐8‐1, Chuo‐Ku, Chiba‐City 260‐8670, Japan, Tel.: +[81‐43‐226‐2039], Fax: +[81‐43‐226‐2039], E‐mail: kaneda@ 123456chiba-u.jp
                Article
                IJC29903
                10.1002/ijc.29903
                4737347
                26510091
                598b6754-e7b7-4f70-af2b-dfbf7e27c142
                © 2015 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC

                This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 25 April 2015
                : 23 October 2015
                Page count
                Pages: 11
                Funding
                Funded by: Practical Research for Innovative Cancer Control program (to A.K.) and CREST program (to A.K. and M.F.) from Japan Agency for Medical Research and Development
                Funded by: Grant‐in‐Aid from the Ministry of Education, Culture, Sports, Science and Technology (to E.S.); Grant sponsor: Grant‐in‐Aid for JSPS Fellows from Japan Society for Promotion of Science (13J02925 to M.F.)
                Funded by: Uehara Memorial Foundation (to A.K.)
                Funded by: Setsuro Fujii Memorial, Osaka Foundation for Promotion of Fundamental Medical Research (to A.K.)
                Categories
                Cancer Genetics and Epigenetics
                Cancer Genetics and Epigenetics
                Custom metadata
                2.0
                ijc29903
                1 April 2016
                Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.5 mode:remove_FC converted:28.01.2016

                Oncology & Radiotherapy
                colorectal cancer (crc),sessile serrated adenoma/polyp (ssa/p),traditional serrated adenoma (tsa),dna methylation,gene mutation

                Comments

                Comment on this article